Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...

A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...

Patients with scleroderma renal crisis demonstrated specific enrichment of CD14+ monocytes with increased EGR1 expression and activation of NF-κB–related pathways. Trajectory analysis indicated that ...

The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on ...

MANCHESTER, England — Use of immunosuppressive drugs within 5 years of the onset of systemic sclerosis (SSc) did not lower patients’ risk for developing pulmonary arterial hypertension (PAH) but was ...

Please provide your email address to receive an email when new articles are posted on . Patients with systemic sclerosis had increased risk for hematologic and solid organ cancers at 5 years vs. a ...

Please provide your email address to receive an email when new articles are posted on . Risks were particularly high in women who received both systemic and local hormone therapies. Future studies ...

Mediterranean, plant-based, and anti-inflammatory diets are associated with reduced C-reactive protein levels in people with multiple sclerosis.